Leukemia , MDS, Myelodysplastic Syndromes (MDS)
Dr. Hany Elmariah is an Assistant Member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy.
Dr. Elmariah earned his MD and his MS in Biomedical Engineering at the University of Florida. He completed an Internal Medicine Residency at Duke University. Dr. Elmariah recently completed a Hematology and Oncology Fellowship at Johns Hopkins University, where he also served as Chief Fellow.
Dr. Elmariah’s clinical interests focus on transplantation as a curative therapy for hematologic malignancies, particularly leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms (myelofibrosis, chronic myelomonocytic leukemia, chronic myelogenous leukemia). Dr. Elmariah’s research is primarily focused on haploidentical donor blood and marrow transplantation as a strategy to increase donor availability for patients in need of blood or marrow transplantation. He also has an interest in novel cellular therapies as potential cures for myeloid malignancies.
Education & Training
Johns Hopkins Hospital - Hematology and Oncology
Duke University Medical Center - Internal Medicine
Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, Lawrence HR, Blazar BR, Anasetti C, Sebti SM, Betts BC. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clin Cancer Res. 2021 May.27(10):2712-2722. Pubmedid: 33753457. Pmcid: PMC8127396.
Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: 33635333. Pmcid: PMC7948297.
Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021 Mar. Pubmedid: 33658647.
Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526.
Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Mar. Pubmedid: 33798768.
Elmariah H, Brunstein CG, Bejanyan N. Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation. Life (Basel). 2021 Jan.11(2). Pubmedid: 33572932. Pmcid: PMC7911120.
Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021 Feb.5(4):975-983. Pubmedid: 33576783. Pmcid: PMC7903230.
DeZern AE, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston ND, Ambinder RF, Brodsky RA, Cooke K, Luznik L, Fuchs EJ, Bolaños-Meade J, Jones RJ. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biol Blood Marrow Tr. 2020 Nov.26(11):2075-2081. Pubmedid: 32818556.
Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J. Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. J Oncol Pract. 2019 Sep.15(9):e825-e834. Pubmedid: 31386608. Pmcid: PMC6743220.
Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Tr. 2018 May.24(5):1099-1102. Pubmedid: 29452245. Pmcid: PMC6439277.
Elmariah H, Shanbhag S. Pan-pseudothrombocytopenia: An unusual case of platelet clumping. Am J Hematol. 2018 Jan. Pubmedid: 29341241.
Elmariah H, Thomas S, Boggan JC, Zaas A, Bae J. The Burden of Burnout. Am J Med Qual. 2017 Mar.32(2):156-162. Pubmedid: 26917807.
Elmariah H, Pratz KW. Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia. J Natl Compr Canc Ne. 2017 Jul.15(7):959-966. Pubmedid: 28687582.
Elmariah H, Garrett ME, De Castro LM, Jonassaint JC, Ataga KI, Eckman JR, Ashley-Koch AE, Telen MJ. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014 May.89(5):530-535. Pubmedid: 24478166. Pmcid: PMC3988218.
Rajasekhar A, Elmariah H, Lottenberg L, Beyth R, Lottenberg R, Ang D. Inferior vena cava filters in trauma patients: a national practice patterns survey of U.S. Trauma centers. Am Surg. 2014 Dec.80(12):1237-1244. Pubmedid: 25513923.
Welch DE, Elmariah H, Peden MC, Adams SG, Ratnakaram R, Kaushal S. Short-term response of macular oedema to intravitreal bevacizumab. Br J Ophthalmol. 2009 Aug.93(8):1033-1036. Pubmedid: 19403519.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub